Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03671811
Recruitment Status : Recruiting
First Posted : September 14, 2018
Last Update Posted : June 16, 2022
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
City of Hope Medical Center

Brief Summary:
This phase II trial studies how well megestrol acetate with or without pterostilbene works in treating patients with endometrial cancer undergoing hysterectomy. Drugs used in chemotherapy, such as megestrol acetate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pterostilbene is an antioxidant found in blueberries or grapes, and it has been shown to be effective in killing tumor cells and reducing cancer burden. It is not yet known whether giving megestrol acetate with or without pterostilbene may work better in treating patients with endometrial cancer.

Condition or disease Intervention/treatment Phase
Atypical Endometrial Hyperplasia Endometrial Carcinoma Drug: Megestrol Acetate Biological: Pterostilbene Phase 2

Detailed Description:

PRIMARY OBJECTIVE:

I. Determine the effect of megestrol acetate (MA) plus pterostilbene (PTE) versus MA alone on tumor proliferation (Ki-67) during the preoperative window in patients with endometrial cancer (EC) who are scheduled for hysterectomy.

EXPLORATORY OBJECTIVES:

I. Determine the effect of MA plus PTE versus MA alone on histologic response during the preoperative window in patients with EC or endometrial complex atypical hyperplasia who are scheduled for hysterectomy.

II. Explore biological characteristics of tumors to determine potential biomarkers which could select for treatment eligibility in future studies.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive pterostilbene orally (PO) twice daily (BID) and megestrol acetate PO BID for 3 weeks in the absence of disease progression or unaccepted toxicity.

ARM II: Patients receive megestrol acetate PO BID for 3 weeks in the absence of disease progression or unaccepted toxicity.

After completion of study treatment, patients are followed up at 6 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label Randomized Phase II Trial of Megestrol Acetate With or Without Pterostilbene in Patients With Endometrial Cancer Scheduled for Hysterectomy
Actual Study Start Date : December 7, 2018
Estimated Primary Completion Date : December 7, 2023
Estimated Study Completion Date : December 7, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hysterectomy

Arm Intervention/treatment
Experimental: Arm I (pterostilbene, megestrol acetate)
Patients receive pterostilbene PO BID and megestrol acetate PO BID for 3 weeks in the absence of disease progression or unaccepted toxicity.
Drug: Megestrol Acetate
Given PO
Other Names:
  • 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
  • 17.alpha.-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
  • 6-Dehydro-6-methyl-17.alpha.-acetoxyprogesterone
  • 6-Methyl-6-dehydro-17.alpha.-acetoxyprogesterone
  • BDH 1298
  • BDH-1298
  • Maygace
  • Megace
  • Megestat
  • Megestil
  • Niagestin
  • Ovaban
  • Pallace
  • SC-10363

Biological: Pterostilbene
Given PO
Other Names:
  • 3'',5''-Dimethoxy-4-stilbenol
  • 3,5-Dimethoxy-4''-hydroxystilbene
  • Trans-3,5-dimethoxy-4-hydroxystilbene

Experimental: Arm II (megestrol acetate)
Patients receive megestrol acetate PO BID for 3 weeks in the absence of disease progression or unaccepted toxicity.
Drug: Megestrol Acetate
Given PO
Other Names:
  • 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
  • 17.alpha.-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
  • 6-Dehydro-6-methyl-17.alpha.-acetoxyprogesterone
  • 6-Methyl-6-dehydro-17.alpha.-acetoxyprogesterone
  • BDH 1298
  • BDH-1298
  • Maygace
  • Megace
  • Megestat
  • Megestil
  • Niagestin
  • Ovaban
  • Pallace
  • SC-10363




Primary Outcome Measures :
  1. Tumor Ki-67 proliferation index [ Time Frame: Pre- and post-treatment up to 6 weeks ]
    Ki-67 represents a specific nuclear marker for cell proliferation that is measured by staining with specific antibodies by immunohistochemical (IHC) staining. The Ki-67 proliferation index is defined as percent tumor cells staining positive, and measured on a continuous scale of 0-100%, with higher values indicating higher proliferation. We will compare treatment-associated change in Ki-67 proliferation index between the 2 study arms, using a 1-sided test with significance at p < 0.05. Ki-67 values will be assessed at two time-points during this study, prior to treatment with megace +/- pterostilbene (pre-treatment), and following completion of treatment (post-treatment). Using a generalized estimating equation to take into account the repeated assessment of subjects (pre and post treatment), analysis will use a generalized linear regression model of Ki-67 index. Adjustment for potential confounding factors will be made as appropriate.


Secondary Outcome Measures :
  1. Histologic response of gland cellularity [ Time Frame: Up to 6 weeks ]
    These histologic changes represent measures of growth and apoptosis, and will be separately scored in the pretreatment endometrial sample and the section of tumor from the hysterectomy (post-treatment sample). Gland cellularity will be assessed by counting the number of cells in one quarter of a high-power field (HPF) (average of 3 fields). This secondary outcome measure will be entered into a generalized linear regression model (with Poisson distribution in the case of count data) to explore whether the effect of treatment differs between treatment arms.

  2. Histologic response of mitotic index [ Time Frame: Up to 6 weeks ]
    These histologic changes represent measures of growth and apoptosis, and will be separately scored in the pretreatment endometrial sample and the section of tumor from the hysterectomy (post-treatment sample). The mitotic index will be calculated as the number of mitoses per HPF (average of 3 fields). This secondary outcome measure will be entered into a generalized linear regression model (with Poisson distribution in the case of count data) to explore whether the effect of treatment differs between treatment arms.

  3. Histologic response of metaplasia [ Time Frame: Up to 6 weeks ]
    These histologic changes represent measures of growth and apoptosis, and will be separately scored in the pretreatment endometrial sample and the section of tumor from the hysterectomy (post-treatment sample). The percentages of tumor that display squamous or mucinous metaplasia will be estimated as percentages, with < 10% considered negative and >= 10% as positive. This secondary outcome measure will be entered into a generalized linear regression model (with Poisson distribution in the case of count data) to explore whether the effect of treatment differs between treatment arms.

  4. Histologic response of eosinophilic cytoplasm [ Time Frame: Up to 6 weeks ]
    These histologic changes represent measures of growth and apoptosis, and will be separately scored in the pretreatment endometrial sample and the section of tumor from the hysterectomy (post-treatment sample). The percentages of tumor that display cytoplasmic eosinophilia will be estimated as percentages, with < 10% considered negative and >= 10% as positive. This secondary outcome measure will be entered into a generalized linear regression model (with Poisson distribution in the case of count data) to explore whether the effect of treatment differs between treatment arms.

  5. Immunohistochemical expression of Bcl-2 to assess tumor growth and apoptosis [ Time Frame: Pre- and post-treatment up to 6 weeks ]
    Immunohistochemistry stains with antibodies directed against Bcl-2 will be performed on pre- and post-treatment endometrial samples. Samples will be scored on a continuous scale (0-100%) using the product of the intensity of cytoplasmic staining, and the proportion of cells staining based on the distribution of staining. This secondary outcome measure will be entered into a generalized linear regression model (with Poisson distribution in the case of count data) to explore whether the effect of treatment differs between treatment arms.

  6. Immunohistochemical expression of Casp3 to assess tumor growth and apoptosis [ Time Frame: Pre- and post-treatment up to 6 weeks ]
    Immunohistochemistry stains with antibodies directed against Casp3 to assess apoptosis will be performed on pre- and post-treatment endometrial samples. Samples will be scored by counting the number of positive staining nuclei per HPF. This secondary outcome measure will be entered into a generalized linear regression model (with Poisson distribution in the case of count data) to explore whether the effect of treatment differs between treatment arms.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented informed consent of the participant and/or legally authorized representative
  • Willing to undergo an intraoperative biopsy/or standard of care tissue collection during surgery, following completion of treatment with MA +/- PTE
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Histologically confirmed EC or complex atypical hyperplasia of the endometrium
  • Candidate for a total hysterectomy with or without bilateral salpingo-oophorectomy
  • About to initiate preoperative window period, with planned hysterectomy scheduled
  • Platelets >= 100,000/mm^3

    • NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement
  • Total bilirubin =< 1.5 X upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) =< 1.5 x ULN
  • Alanine aminotransferase (ALT) =< 1.5 x ULN
  • Creatinine clearance of >= 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula
  • Women of childbearing potential: negative urine or serum pregnancy test in premenopausal women. Postmenopausal women do not need to undergo a pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required

Exclusion Criteria:

  • Pterostilbene supplements within 30 days prior to day 1 of protocol therapy
  • Any of the following phytochemical-based supplements within 30 days prior to day 1 of protocol therapy: resveratrol, genistein, and quercetin
  • Chemotherapy for EC
  • Allergic reaction/hypersensitivity to similar agents, excipients
  • Unstable cardiac disease as defined by one of the following:

    • Cardiac events such as myocardial infarction (MI) within the past 6 months
    • NYHA (New York Heart Association) heart failure class III-IV
    • Uncontrolled atrial fibrillation or hypertensive emergency/urgency (defined as systolic blood pressure >= 180 mmHg and/or diastolic blood pressure >= 120 mmHg)
  • Active or history of recent thromboembolism or stroke, within the past 6 months
  • Cushing's syndrome
  • Acute infection requiring systemic (intravenous) treatment
  • Known history of human immunodeficiency virus (HIV) infection
  • Known active hepatitis B or C infection
  • Inability to swallow tablets/capsules
  • Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues, etc
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03671811


Locations
Layout table for location information
United States, California
City of Hope Medical Center Recruiting
Duarte, California, United States, 91010
Contact: Thanh H. Dellinger    626-218-1379    tdellinger@coh.org   
Principal Investigator: Thanh H. Dellinger         
Sponsors and Collaborators
City of Hope Medical Center
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Thanh H Dellinger City of Hope Medical Center
Layout table for additonal information
Responsible Party: City of Hope Medical Center
ClinicalTrials.gov Identifier: NCT03671811    
Other Study ID Numbers: 17327
NCI-2018-01555 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
17327 ( Other Identifier: City of Hope Comprehensive Cancer Center )
P30CA033572 ( U.S. NIH Grant/Contract )
First Posted: September 14, 2018    Key Record Dates
Last Update Posted: June 16, 2022
Last Verified: June 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Endometrial Neoplasms
Endometrial Hyperplasia
Hyperplasia
Pathologic Processes
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Diseases
Megestrol
Megestrol Acetate
Contraceptives, Oral, Hormonal
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptive Agents, Hormonal
Contraceptives, Oral, Synthetic
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Appetite Stimulants
Central Nervous System Stimulants